Clinical trials: Head or Neck Cancer
Lip, Lip Cancer
T1 Squamous Cell Carcinomas of the Lip
The purpose of this study is to investigate the risk of recurrence and metastasis in patients treated with different surgical margins (5mm vs 10mm) for a T1 squamous cell carcinoma of the lip.
- Conditions
- Lip, Lip Cancer, Lip SCC, Squamous Cell Carcinoma
- Trial name
- NCT05610293
- Where
- 3 sites in Netherlands
- Volunteers
- 300 people
- Sponsor
- Maastricht University Medical Center
Upper Aerodigestive Tract Neoplasms
Evaluation of Low-Level Laser Therapy Efficacy in Pain Management of Grade 2 Oral Mucositis Induced by Radiotherapy or Chemoradiotherapy: a Study in Patients With Upper Aerodigestive Tract Cancer
Prospective, monocentric, randomized phase II study evaluating Low-Level Laser Therapy (LLLT) as a treatment for the pain due to grade 2 oral mucositis in patients with upper aero-digestive tract cancer treated by radiotherapy or…
- Trial name
- ESMULLLAT (NCT03955224)
- Testing
- Basic Oral Care + active LLLT, Basic oral Care + inactive LLLT, Basic Oral Care
- Where
- France
- Sponsor
- Institut Claudius Regaud
Head Neck, Squamous Cell Carcinoma of Head and Neck
Phase II Trial of Magrolimab and Cetuximab With Pembrolizumab or Docetaxel for Recurrent/Metastatic Head Neck Squamous Cell Carcinoma
To learn if magrolimab, along with a combination of commercially-available drugs (cetuximab, pembrolizumab, and docetaxel) can help to control HNSCC in combination with other drugs. The safety of magrolimab will also be studied.
- Trial name
- NCT06046482
- Testing
- Pembrolizumab, Magrolimab, cetuximab
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- M.D. Anderson Cancer Center
Medullary Thyroid Cancer (MTC), Differentiated Thyroid Cancer (DTC)
Nintedanib(BIBF1120) in Thyroid Cancer
For the treatment of thyroid cancer with the so called targeted therapy the angiogenesis pathway has several potential targets. The Receptors for Vascular endothelial growth factor (VEGF) and especially VEGFR-2 is considered to…
- Trial name
- NCT01788982
- Testing
- Nintedanib
- Where
- 27 sites in Belgium, Denmark and 7 more
- Volunteers
- 100 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Esophageal Cancer
Paclitaxel and Capecitabine in Patients With Metastatic/Recurrence Esophageal Cancer
Capecitabine is an orally administered fluoropyrimidine that is converted by 5-FU by thymidine phosphorylase (TP), preferentially in tumor tissues and has demonstrated activity as single agent in patients with gastrointestinal…
- Trial name
- NCT00453323
- Testing
- Paclitaxel, Capecitabine
- Where
- South Korea
- Volunteers
- 33 people
- Sponsor
- National Cancer Center, Korea
Early Esophageal Cancer or Precancerous Lesions Treated With Endoscopic Resection
The Cohort Study of Early Esophageal Cancer or Precancerous Lesions Treated With Endoscopic Resection
Endoscopic Submucosal Dissection (ESD) is currently the main method of treatment of early esophageal cancer and precancerous lesions.
- Trial name
- NCT03377972
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Shanghai Zhongshan Hospital
Pancreatic Adenocarcinoma, Cholangiocarcinoma
Clinical Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Patients With Taxans-resistant Pancreatic Adenocarcinoma, Cholangiocarcinoma, Lung Cancer, Gastric Cancer, Esophageal Carcinoma, or Breast Cancer
This study is a single-center, single-arm, open-label, phase II clinical trial designed to evaluate the efficacy and safety of Paclitaxel Polymeric Micelles for Injection for the treatment of patients with advanced pancreatic…
- Conditions
- Pancreatic Adenocarcinoma, Cholangiocarcinoma, Lung Cancer, Stomach Cancer
- Trial name
- NCT06199895
- Testing
- Paclitaxel Polymeric Micelles for Injection
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Liu Huang
Solid Tumor, Adult, Epithelial Ovarian Cancer
Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors
This is a first-in-human, Phase 1/2 open-label, multicenter, dose-escalation, safety, pharmacokinetics (PK), and biomarker study of CBX-12 in subjects with advanced or metastatic refractory solid tumors.
- Conditions
- Solid Tumor, Adult, Epithelial Ovarian Cancer, Small Cell Lung Carcinoma, Breast Cancer
- Trial name
- NCT04902872
- Testing
- CBX-12
- Where
- 4 sites in United States
- Volunteers
- 69 people
- Sponsor
- Cybrexa Therapeutics
Carcinoma
A Non Interventional Study With Doce Onkovis (Docetaxel) Utilized for the Treatment of Cancer
The main purpose of this observational study with Docetaxel is to determine the number of treatment cycles and the quantity of Doce onkovis needed therefore under the special circumstance of ambulant chemotherapy.
- Trial name
- NCT01614002
- Where
- 23 sites in Germany
- Volunteers
- 371 people
- Sponsor
- Onkovis GmbH
Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
A Comprehensive Multiomic Biomarker Evaluation Across Two Single-arm Cohorts to Elucidate Mechanisms of Response and Resistance in Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC)
The BeeHive study is an investigator-initiated, single center, open-label phase II clinical trial that is designed to conduct a comprehensive multiomic biomarker evaluation across two single-arm cohorts to elucidate mechanisms of…
- Trial name
- BeeHive (NCT07408063)
- Testing
- GSK5764227, Dostarlimab
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- University Health Network, Toronto
Esophagus Cancer, Esophagogastric Junction Cancer
MRI and CT Simulation in the Evaluation of Tumor Response and Target Volume Definition for Esophageal or Esophagogastric Cancer Patients Undergoing Chemoradiotherapy
Magnetic resonance imaging (MRI) with functional features of diffusion weighted imaging (DWI) are advancing imaging technologies that have potential to overcome limitations of conventional staging methods, radiation treatment…
- Trial name
- NCT02988921
- Testing
- MRI and CT, Ratiotherapy, Paclitaxel, platinum-based drug
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Oral Squamous Cell Carcinoma
Concurrent Radiotherapy and/or Cisplatin With or Without Celecoxib in Patients With Primary Oral Squamous Cell Carcinoma
The research and development of novel anti-tumor agents in oral cancer is slow, the investigation of repositioning use of currently available drugs in clinical, such as a selective cyclooxygenase-2 (COX-2) inhibitor…
- Trial name
- NCT02739204
- Testing
- Celecoxib
- Where
- Taiwan
- Volunteers
- 270 people
- Sponsor
- China Medical University Hospital
Esophageal Cancer
Clinical Trial Evaluating TQB6411 Injection in Participant s With Esophageal Cancer
The Phase Ib stage of this study primarily aims to evaluate the tolerance and safety of TQB6411 Injection in participants with recurrent or metastatic Esophageal cancer who have previously failed treatment with PD-1/PD-L1…
- Trial name
- NCT07367516
- Testing
- TQB6411 Injection
- Where
- 30 sites in China
- Volunteers
- 105 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Head and Neck Squamous Cell Carcinoma
AK117 (Anti-CD47 mAb) Plus Cetuximab as Second-Line Therapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
The administration of first-line pembrolizumab monotherapy or combined chemotherapy has been shown to improve survival among patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC).
- Trial name
- NCT06508606
- Testing
- AK117 + Cetuximab
- Where
- China
- Volunteers
- 10 people
- Sponsor
- West China Hospital
Head and Neck Tumors
Tislelizumab Combined APF Chemotherapy in the Treatment of Locally Advanced Head and Neck Tumors
The goal of this clinical trial is to test in describe participant population. The main questions it aims to answer are: 1. evaluate the efficacy and safety of tislelizumab combined with APF sequential surgery or radical…
- Trial name
- NCT05758389
- Testing
- Tislelizumab, Paclitaxel (albumin-bound type), Cisplatin, 5-FU
- Where
- China
- Volunteers
- 29 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Squamous Cell Carcinoma of the Head and Neck
Preoperative Administration of Olaparib With Cisplatin or With Durvalumab or Alone or no Tratment in Patients Who Are Candidates for Surgery of Carcinoma of the Head and Neck.
OPHELIA (OPHELIA (OlaParib and durvalumab in HEad and neck squamous celL carcInomA) trial is a Greek, investigator-initiated, randomized open-label window-of-opportunity phase II study.
- Trial name
- OPHELIA (NCT02882308)
- Testing
- Olaparib, Cisplatin, Durvalumab
- Where
- 2 sites in Greece
- Volunteers
- 41 people
- Sponsor
- Hellenic Cooperative Oncology Group
Nasopharyngeal Neoplasms
Safety and Efficacy of CC-486 in Previously Treated Patients With Locally Advanced or Metastatic Nasopharyngeal Carcinoma
The purpose of this study is to evaluate the safety and efficacy of CC-486 in previously treated patients with locally advanced or metastatic nasopharyngeal carcinoma having failed one to two previous regimens, including…
- Trial name
- NCT02269943
- Testing
- CC-486
- Where
- 25 sites in United States, Canada and 7 more
- Volunteers
- 36 people
- Sponsor
- Celgene
Squamous Cell Carcinoma of the Head and Neck
Study of LEE011plus Cetuximab in Patients With a Cancer of the Head and Neck
In this trial, the investigators would like to investigate the activity of LEE011 associated with cetuximab (standard of care for the SCCHN patients at this stade of the disease).
- Trial name
- CETLEE011 (NCT02429089)
- Testing
- LEE011
- Where
- 5 sites in Belgium
- Volunteers
- 21 people
- Sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Head and Neck Neoplasms
Study of Monalizumab and Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
The objective of this study is to evaluate in a 3 +3 design, the safety of escalating doses of Monalizumab given IV in combination with cetuximab in patients who have received prior systemic regimen(s) for recurrent and/or…
- Trial name
- NCT02643550
- Testing
- Monalizumab, Cetuximab, Anti-PD(L)1
- Where
- 18 sites in United States, France
- Volunteers
- 143 people
- Sponsor
- Innate Pharma
Insular Thyroid Cancer, Recurrent Thyroid Cancer
Suberoylanilide Hydroxamic Acid in Treating Patients With Metastatic and/or Locally Advanced or Locally Recurrent Thyroid Cancer
This phase II trial is studying how well suberoylanilide hydroxamic acid works in treating patients with metastatic and/or locally advanced or locally recurrent thyroid cancer.
- Conditions
- Insular Thyroid Cancer, Recurrent Thyroid Cancer, Stage II Follicular Thyroid Cancer, Stage II Papillary Thyroid Cancer
- Trial name
- NCT00134043
- Testing
- vorinostat
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- National Cancer Institute (NCI)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.